Literature DB >> 15784653

Protective mechanisms of a metalloporphyrinic peroxynitrite decomposition catalyst, WW85, in rat cardiac transplants.

Galen M Pieper1, Vani Nilakantan, Min Chen, Jing Zhou, Ashwani K Khanna, James D Henderson, Christopher P Johnson, Allan M Roza, Csaba Szabó.   

Abstract

Nitric oxide (NO) derived from inducible NO synthase has been implicated in cardiac rejection. However, little is known about the role of the reactive nitrogen species peroxynitrite. We examined the protective actions of a peroxynitrite decomposition catalyst, WW85, in an experimental model of acute cardiac rejection. Heterotopic, abdominal transplantation of rat donor hearts was performed. Groups included isografts, allografts, or allografts treated with WW85, cyclosporine, or cyclosporine + WW85. We determined graft survival, histological rejection, and graft function (by in situ sonomicrometry). Intragraft biochemical analysis of cytokines and proapoptotic and antiapoptotic gene expression using reverse transcriptase-polymerase chain reaction were determined. Treatment with WW85 or cyclosporine alone prolonged graft survival, improved graft function, and decreased histological rejection. Graft survival was further significantly (P < 0.001) enhanced by combination treatment. A decrease was also shown in nitrotyrosine, poly(ADP-ribose) polymerase (PARP) activation, and lipid peroxide formation by WW85 that was potentiated when given in combination with cyclosporine. Benefits could not be ascribed to changes in intragraft myeloperoxidase activity. Only combination therapy produced significant decreases in inflammatory cytokine gene expression, suggesting that WW85 acted primarily downstream of these stimuli. In general, WW85 had no direct action on expression of the proapoptotic gene, Fas ligand; however, WW85 given alone or with cyclosporine enhanced expression of antiapoptotic genes Bcl-2 and Bcl-xL. Collectively, these findings suggest a protective action of the peroxynitrite decomposition catalyst WW85 on graft rejection that is independent of any action on leukocyte sequestration and cytokine gene expression. Rather, effects seem to be downstream on decreased protein nitration, decreased lipid peroxidation, and decreased PARP activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784653     DOI: 10.1124/jpet.105.083493

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Catalytic peroxynitrite decomposition improves reperfusion injury after heart transplantation.

Authors:  Gábor Szabó; Sivakkanan Loganathan; Béla Merkely; John T Groves; Matthias Karck; Csaba Szabó; Tamás Radovits
Journal:  J Thorac Cardiovasc Surg       Date:  2012-03-07       Impact factor: 5.209

2.  Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway.

Authors:  Rosanna Vaschetto; Jan W Kuiper; René J P Musters; Etto C Eringa; Francesco Della Corte; Kanneganti Murthy; A B Johan Groeneveld; Frans B Plötz
Journal:  Crit Care       Date:  2010-03-26       Impact factor: 9.097

3.  The peroxynitrite catalyst WW-85 improves microcirculation in ovine smoke inhalation injury and septic shock.

Authors:  Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Martin Westphal; Lillian D Traber; Andrew L Salzman; David N Herndon; Daniel L Traber
Journal:  Burns       Date:  2011-02-22       Impact factor: 2.744

4.  The peroxynitrite catalyst WW-85 improves pulmonary function in ovine septic shock.

Authors:  Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Robert A Cox; Martin Westphal; Levente Kiss; Eszter M Horvath; Lillian D Traber; Hal K Hawkins; Andrew L Salzman; Garry J Southan; David N Herndon; Daniel L Traber
Journal:  Shock       Date:  2011-02       Impact factor: 3.454

5.  Lung-protective effects of the metalloporphyrinic peroxynitrite decomposition catalyst WW-85 in interleukin-2 induced toxicity.

Authors:  Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Martin Westphal; Lillian D Traber; Perenlei Enkhbaatar; Kanneganti G K Murthy; Yoshimitsu Nakano; Andrew L Salzman; David N Herndon; Daniel L Traber
Journal:  Biochem Biophys Res Commun       Date:  2008-10-23       Impact factor: 3.575

Review 6.  The complex role of iNOS in acutely rejecting cardiac transplants.

Authors:  Galen M Pieper; Allan M Roza
Journal:  Free Radic Biol Med       Date:  2008-02-07       Impact factor: 7.376

7.  Treatment with insulin inhibits poly(ADP-ribose)polymerase activation in a rat model of endotoxemia.

Authors:  Eszter M Horváth; Rita Benko; Domonkos Gero; Levente Kiss; Csaba Szabó
Journal:  Life Sci       Date:  2007-11-21       Impact factor: 5.037

Review 8.  Simple biological systems for assessing the activity of superoxide dismutase mimics.

Authors:  Artak Tovmasyan; Julio S Reboucas; Ludmil Benov
Journal:  Antioxid Redox Signal       Date:  2013-10-19       Impact factor: 8.401

Review 9.  SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways.

Authors:  Ines Batinic-Haberle; Artak Tovmasyan; Emily R H Roberts; Zeljko Vujaskovic; Kam W Leong; Ivan Spasojevic
Journal:  Antioxid Redox Signal       Date:  2013-10-01       Impact factor: 8.401

Review 10.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.

Authors:  Pal Pacher; Csaba Szabo
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.